Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Cyclophosphamide-Driven Efficacy in GVHD Unaffected by Matched Unrelated Donor Status

Virginia Powers, PhD
Published: Wednesday, Apr 03, 2019

blood cellsCyclophosphamide administered alone or in combination with other agents is an effective prophylactic treatment for graft-versus-host disease (GVHD), regardless of stem cell source, conditioning intensity, or patient age in 10/10 and 9/10 human leukocyte antigen (HLA) matched unrelated donor (MUD) hematopoietic stem cell transplantation (HSCT) recipients, according to findings presented at the 2019 European Society for Blood and Marrow Transplantation Annual Meeting.

Improved non-relapse mortality (NRM) rates were observed in both 10/10 and 9/10 MUD patients with cyclophosphamide, demonstrating similar incidence rates of acute and chronic GVHD.

“PTCy is successfully used as a GVHD-prophylaxis backbone in haplo-identical transplantation; these encouraging results prompted us to assess PTCy in the unrelated donor setting, said Francesca Lorentino, MD, of the San Raffaele Scientific Institute, Hematology and Bone Marrow Transplantation Unit in Milan, Italy, who presented the results on behalf of the Acute Leukemia Working Party (ALWP) of the EBMT.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication